Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Parallel Group, Double-blind, Phase 2 Trial to Evaluate Efficacy and Safety of SCM-CGH in Patients With Steroid-Refractory or Dependent Chronic Graft-Versus-Host Disease

Next Previous
Search
Trial Profile

A Multicenter, Randomized, Parallel Group, Double-blind, Phase 2 Trial to Evaluate Efficacy and Safety of SCM-CGH in Patients With Steroid-Refractory or Dependent Chronic Graft-Versus-Host Disease

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SCM CGH (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Acronyms SCM-CGH2001
  • Sponsors SCM Lifescience

    • Most Recent Events

    • 07 Jun 2023 Planned number of patients changed from 77 to 84.
    • 07 Jun 2023 Planned End Date changed from 31 Dec 2022 to 30 Sep 2024.
    • 07 Jun 2023 Planned primary completion date changed from 31 Mar 2022 to 31 Mar 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top